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Objective: To identify and to determine the antimicrobial susceptibility of Acinetobacter
baumannii (A. baumannii) clinical isolates from ICU at Aseer Central Hospital.
Methods: The study was conducted in the Intensive Care Unit, Aseer Central Hospital,
Saudi Arabia over 13 months period (2014–2015). Acinetobacter species (n = 105) were
isolated from various clinical samples. Isolates were identiﬁed using selected phenotypic
criteria and conﬁrmed using the Vitek 2 automated system. This system was used to
determine the susceptibilities of 21 antimicrobial agents. Patients, isolates and drug data
were analyzed using the SPSS statistical software package to determine some epidemi-
ological and microbiological patterns.
Results: Of the 105 stains, A. baumannii accounted for 49 (46.67%), A. baumannii
complex, 19 (18.09%), A. baumannii/haemolyticus 32 (30.47), Acinetobacter haemoly-
ticus 4 (3.81%), Acinetobater lwofﬁi 1 (0.95%) and unidentiﬁed Acinetobater species 2
(1.3%). Of the 105 Acinetobacter strains, 103 (98.1%) were found multidrug resistant
(MDR). A. baumannii strain were 100% sensitive to colistin and 74.5% to
trimethoprim + sulfamethoxazole. The remaining 19 antimicrobial agents revealed low or
no sensitivities: amikacin 16.3%; ampicillin 7.7%; ceftazidime, 7.3%. Distribution of
similar sensitivities was shown by other Acinetobacter species. Mean number of isolates
from males and females indicates no statistical variation (P = 0.867) whereas age groups
showed signiﬁcant differences (P = 0.008) as it is clear from the high percentage of
infected individuals more than 60 years followed by those aged 20–29 years old
(19.05%). Upper respiratory tract (30.48%), lower respiratory tract (47.65%) and sub-
cutaneous tissue (9.5%) were the main sources of Acinetobacter spp. but mean numbers
of isolates from these specimens indicate no discrepancy between specimens (P = 0.731).
Conclusions: Acinetobacter species including A. baumannii were found MDR (98.1%)
according to the current Acinetobacter spp. antimicrobial categorization. Approximately
half of these strains were A. baumannii. All Acinetobacter species were 100% sensitive to
colistin and to some extent to trimethoprim + sulfamethoxazole (74.5%). ICU-acquired
pneumonia among patients over 60 years of age who spend prolong times at artiﬁcial
ventilations made up the majority of the cases.1. Introduction
Acinetobacter species especially Acinetobacter baumannii
(A. baumannii) are emerging as a serious cause of health care-associated infections especially in intensive care units (ICU).
The rising numbers of multi-drug resistant (MDR) Acinetobacter
species have limited the therapeutic choices for infections con-
trol [1]. Infections in crucially sick cancer patients have
augmented mortality and added to the ICU stay [2].
Acinetobacter associated infections represent a tough challenge
to control in seriously sick patients especially those in ICU. Aci-
netobacter species have the capacity to acquire resistance to almost
all presently existing antimicrobial agents [3]. Also, ICU admissionrticle under the CC BY-NC-ND license (http://
Figure 1. Identities of Acinetobacter species recovered from 105 patients
at the ICU, Aseer Central Hospital (2014–2015).
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the risk of ventilator-associated pneumonia [4]. A. baumannii was
found the most common and increasingly important pathogen
associated with ventilator-associated pneumonia particularly the
late-onset and recurrent ventilator-associated pneumonia in a ter-
tiary care hospital in Riyadh, Saudi Arabia [5]. A retrospective
study conducted between 2005 and December 2010 in Riyadh
region indicated that there was a signiﬁcant increase in
antimicrobial resistance A. baumannii [6].
A. baumannii is ubiquitous which may be found in food,
water and soils as well as on the skin of healthy human. Strains
of A. baumannii endure adverse environmental condition such as
dryness for long time [7]. Such characteristics help A. baumannii
to spread easily by all potential routes. Clinical health workers in
all hospital sections stated the danger of A. baumannii but the
problems is much worse in internal medicine or ICU.
Variations in recording A. baumannii among wards could be a
result of selective pressure induced on organisms generated by
the random unsupervised use of broad-spectrum antibiotics [8].
In recent years, A. baumannii showed a radical decrease in
susceptibility to carbapenems. The main carbapenem resistance
mechanism was found due to class D-OXA-type enzymes (oxa-
23 and oxa-24/40) with carbapenemase activity. The authors
concluded that this is a key epidemiological worry as medicinal
choices turn out to be narrow. Doctors will rely on polymyxin in
combinations with other antibiotics [9]. Recent study reported
the appearance of ST236 in Saudi Arabia and Egypt, and the
spread of carbapenem resistant A. baumannii clones belonging
to ST884, ST945 and ST1096 in Saudi Arabia [10].
Our current understanding of the Acinetobacter associated
illness as emerging problem is lacking. Prevalence, risk factors and
antimicrobial sensitivity patterns in Saudi Arabia and Aseer region
in particular are still need to be determined. One study which was
conducted during 2011/2012 at Aseer Central Hospital indicated
that all isolates were sensitive to imipramine, meropenem and
colistin and showed high resistant to nitrofurantoin and cefoxitin
but least resistant to imipenem and ticarcillin. These authors ex-
press worry on the rising resistant to antibiotics [11]. The purpose of
the work was to establish the magnitude of A. baumannii
associated with infections in Aseer region and their antimicrobial
proﬁle in the southern Saudi Arabia. Publishing such information
will establish database and will assist authorities to establish
policies towards controlling the infections.
This study aimed to identify and to determine the antimi-
crobial susceptibility of A. baumannii clinical isolates from ICU
at Aseer Central Hospital.
2. Materials and methods
2.1. Ethical approval
The present research was approved by the College of Med-
icine Ethical Committee. Individual consent from each patient
was overlooked by the committee because of the retrospective
nature of the study.
2.2. Study design and subjects
In this observational study, adult patients (n = 105) were
admitted to the intensive care unit (ICU), Aseer Central Hospital
during 2014 and 2015 and were retrospectively evaluated.2.3. Bacterial isolates
Acinetobacter species were isolated from 105 ICU hospital-
ized infected patients over a 13 month period, Feb. 2014 to Feb.
2015. Isolates were identiﬁed using selected phenotypic criteria
and conﬁrmed using the Vitek 2 automated system. Samples
were processed for culture by standard conventional methods
and preliminary identiﬁcation was performed by gram staining,
culturing on MacConkey's agar. Non-lactose fermenting bacteria
were sub-cultured and incubated for additional overnights.
Genus Acinetobacter was identiﬁed by gram staining, cell and
colony morphology, positive catalase test, negative oxidase test
and absence of motility [7].
2.4. Antibiotic sensitivity
Identiﬁed species were tested (in vitro) against 21 antibacterial
drugs using the Vitek 2 automated system. Antibiotics and their
strength used were according to the Clinical and Laboratory
Standards Institute guidelines [7]. The tested antimicrobial agents
were: amikacin, ampicillin, aztreonam, cefepime, cefotaxime,
ceftazidime, ciproﬂoxacin, colistin, fosfomycin, gentamicin,
imipenem, levoﬂoxacin, meropenem, mezlocillin, moxiﬂoxacin,
piperacillin, rifampicin, tetracycline, tobramycin, trimethoprim
and trimethoprim + sulfamethoxazole.
2.5. Statistical analysis
Data were examined using SPSS software version16.0.
Univariate analysis of variance was used to compare variation
among means of different variables. P value < 0.05 was
considered as the level of signiﬁcance.
3. Results
3.1. Identiﬁcation of Acinetobater species
Of the 105 stains, A. baumannii accounted for 49 (46.67%),
A. baumannii complex, 19 (18.09%), A. baumannii/haemolyti-
cus 32 (30.47%), Acinetobacter haemolyticus 4 (3.81%), Aci-
netobater lwofﬁi 1 (0.95%) and unidentiﬁed Acinetobater
species 2 (1.3%) (Figure 1).
Table 1
Sensitivity and resistance results of Acinetobacter species of 21 various antimicrobial agents [n (%)].
Antimicrobial
agent
Acinetobacter
baumannii
Acinetobacter
baumannii complex
Acinetobacter
baumannii/
haemolyticus
Acinetobacter
haemolyticus
Acinetobater lwofﬁi
S R S R S R S R S R
Amikacin 8 (16.3) 41 (83.7) 0 (0.0) 3 (100.0) 6 (18.8) 26 (81.3) 3 (75.0) 1 (25.0) 1 (100.0) 0 (0.0)
Ampicillin 1 (7.7) 12 (92.3) 0 (0.0) 16 (100.0) 0 (0.0) 1 (100.0) 0 (0.0) 1 (100.0) 0 (0.0) 0 (0.0)
Aztreonam 2 (8.0) 23 (92.0) 0 (0.0) 18 (100.0) 0 (0.0) 24 (100.0) 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
Cefepime 1 (3.4) 28 (96.6) 0 (0.0) 18 (100.0) 3 (11.5) 23 (88.5) 1 (25.0) 3 (75.0) 1 (100.0) 0 (0.0)
Cefotaxime 1 (2.2) 45 (97.8) 0 (0.0) 15 (100.0) 2 (6.5) 29 (93.5) 0 (0.0) 3 (100.0) 0 (0.0) 0 (0.0)
Ceftazidime 3 (7.3) 38 (92.7) 0 (0.0) 19 (100.0) 2 (6.9) 27 (93.1) 1 (50.0) 1 (50.0) 1 (100.0) 0 (0.0)
Ciproﬂoxacin 3 (6.1) 46 (93.9) 0 (0.0) 19 (100.0) 3 (9.4) 29 (90.6) 1 (33.3) 3 (66.7) 1 (100.0) 0 (0.0)
Colistin 46 (100.0) 0 (0.0) 13 (100.0) 0 (0.0) 28 (100.0) 0 (0.0) 3 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
Fosfomycin 0 (0.0) 23 (100.0) 0 (0.0) 15 (100.0) 0 (0.0) 24 (100.0) 0 (0.0) 1 (100.0) 0 (0.0) 0 (0.0)
Gentamicin 2 (5.4) 35 (94.5) 3 (25.0) 9 (75.0) 2 (6.7) 28 (93.3) 1 (33.3) 2 (66.7) 1 (100.0) 0 (0.0)
Imipenem 2 (4.5) '42 (95.5) 0 (0.0) 16 (100.0) 0 (0.0) 24 (100.0) 2 (50.0) 2 (50.0) 0 (0.0) 0 (0.0)
Levoﬂoxacin 2 (4.8) 40 (95.2) 0 (0.0) 12 (100.0) 5 (16.1) 26 (83.9) 0 (0.0) 2 (100.0) 1 (100.0) 0 (0.0)
Meropenem 0 (0.0) 46 (100.0) 0 (0.0) 14 (100.0) 0 (0.0) 31 (100.0) 0 (0.0) 2 (100.0) 1 (100.0) 0 (0.0)
Mezlocillin 1 (2.3) 43 (97.7) 0 (0.0) 0 (0.0) 0 (0.0) 28 (100.0) 0 (0.0) 2 (100.0) 0 (0.0) 0 (0.0)
Moxiﬂoxacin 0 (0.0) 39 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 30 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Piperacillin 1 (2.9) 33 (97.1) 0 (0.0) 18 (100.0) 1 (4.5) 21 (95.5) 1 (33.3) 2 (66.7) 1 (100.0) 0 (0.0)
Rifampicin 0 (0.0) 22 (100.0) 9 (100.0) 0 (0.0) 0 (0.0) 24 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Tetracycline 1 (2.3) 43 (97.7) 0 (0.0) 0 (0.0) 1 (3.4) 28 (96.6) 0 (0.0) 2 (100.0) 1 (100.0) 0 (0.0)
Tobramycin 3 (6.8) 41 (93.2) 8 (72.7) 3 (27.3) 4 (12.5) 28 (87.5) 2 (66.7) 1 (33.3) 1 (100.0) 0 (0.0)
Trimethoprim 0 (0.0) 23 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 6 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Trimethoprim +
sulfamethoxazole
35 (74.5) 12 (25.5) 15 (78.9) 4 (21.1) 22 (68.8) 10 (31.3) 2 (50.0) 2 (50.0) 0 (0.0) 1 (100.0)
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Sensitivity and resistance results of Acinetobacter species to
the 21 antimicrobial agents are shown in Table 1. Of the 105
Acinetobacter strains, 103 (98.1%) were found MDR since allFigure 2. Distribution of Acinetobacter species according to sex and age amoMDR were resistant to more than two antimicrobial classes
(Table 1). Results indicated that A. baumannii strains were
sensitive to colistin and 74.5% to trimethoprim + sulfamethox-
azole. The remaining 19 antimicrobial agents revealed low or no
sensitivities: amikacin 16.3%; ampicillin 7.7%; ceftazidime,ng 105 patients attended the ICU, Aseer Central Hospital (2014–2015).
Figure 3. Numbers of Acinetobacter species according specimens types and sex of 105 patients attended the ICU, Aseer Central Hospital (2014–2015).
Ali Al Bshabshe et al./Asian Paciﬁc Journal of Tropical Medicine 2016; 9(9): 903–9089067.3%. Similar sensitivities were shown by other Acinetobacter
species.
Resistance pattern of Acinetobacter species recovered from
105 patients at the ICU, Aseer Central Hospital (2014–2015) is
shown in Table 1. Note all species show high sensitivities to
colistin and to some extent to trimethoprim +
sulfamethoxazole.
3.3. Distribution of Acinetobacter species according to
sex and age group
The majority of the patients were males (63.81%) compared
to females (36.19%) (P = 0.867). Age group more than 60 years
was the major affected groups in the ICU with Acinetobacter
spp. (47.62%) followed by those aged 20–29 years old
(19.05%). These two groups vary signiﬁcantly than other age
groups (P = 0.008) (Figure 2).
3.4. Distribution of Acinetobacter species according to
specimen type
Upper respiratory tract (30.48%), lower respiratory tract
(47.65%) and subcutaneous tissue (9.50%) were the main
sources of Acinetobacter spp. (Figure 3).
4. Discussion
The growing numbers of multi-drug resistant (MDR) Aci-
netobacter species have reduced the medicinal selections for
managing Acinetobacter infections. Acinetobacter species
including the leading species, A. baumannii, are developing as
real infectious threat mainly in intensive care units (ICU). This
study aimed to identify and to establish the antimicrobial proﬁleof A. baumannii isolates from ICU at Aseer Central Hospital.
Hospital units have been the focus of repeated concerns
regarding the rising number of nosocomial infections.
A. baumannii, a gram-negative, non-fermentative and a noted
opportunistic nosocomial pathogenic bacterium which is able of
live for long time in varied environmental conditions including
hospital environment and human body surface [12]. It causes
different nosocomial infections particularly nosocomial
pneumonia, blood infection, urinary tract infection, surgical
wound infection, especially in patients in ICU [13]. Our present
ﬁndings do not differ from the global data. We noticed the
respiratory specimens (upper and lower) from which we have
isolatedAcinetobacter species comprised 80.95%of all specimens.
Antibiotic policies and infection control measures are
considered of immense value in ﬁghting the mounting trends of
nosocomial incidents. Genuine efforts are needed to develop
new antimicrobial agents against these pathogens and to monitor
the efﬁcacy of the presently accessible drugs. For instance, hand
hygiene has been found to have impact in controlling infection
in Aseer Central Hospital [14]. Infections due to drug-resistant
gram-negative rods are an emerging risk factor for increased
mortality in ICU. A number of studies have indicated the rising
trends of pathogens from other body systems and hospital wards
[15,16].
Numerous deﬁnitions have been introduced in medical
literature to describe distinctive patterns of resistance among
pathogen encountered in healthcare settings. Multidrug-resistant
(MDR), extensively-drug resistant (XDR) and pandrug-resistant
(PDR) bacteria are now in use in the medical literature. In this
regard MDR in Acinetobacter spp. is deﬁned as strain which is
found non-susceptible to 1 agent in 3 antimicrobial structural
categories [17]. MDR A. baumannii is recognized globally as an
emerging signiﬁcant health care risk. This bacterium is normally
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treated with colistin, amikacin, or tigecycline [18].
According to the Acinetobacter spp. antimicrobial categories
and agents used to deﬁne MDR, XDR and PDR [17], the number
of MDR identiﬁed in this paper is large (98.1%). One of the
most serious and common risks of infections in ICU is the use
of medical devices and procedures. ICU-acquired pneumonia
(ventilator-associated pneumonia) represents a chief cause of
morbidity and mortality in patients in the ICU worldwide [19].
Our ﬁndings go in line with this fact, we have isolated
Acinetobacter spp. from more than 80% of the specimens of
the ICU patient. Among those the mostly affected with
signiﬁcant ratio (P < 0.05) were those aged above 60 years
(Figure 2). But gender was not signiﬁcant is this distribution.
This age with such risk may be because of the prolong stay
under ventilation.
A. calcoaceticus baumannii complex which had been isolated
from patients at Aseer region [11] have shown 100% sensitivity
to imipramine, meropenem and colistin. Contrary to the
present ﬁnding, all our A. baumannii isolates (n = 49) were
found 100% resistant to meropenem (Table 1) but as expected
colistin sensitivity is in full agreement with the previous work
[11]. A. baumannii was found to have reduced susceptibility to
carbapenems at the Security Forces Hospital in Saudi Arabia
[9]. Studies unveiled that A. baumannii had the uppermost rate
of resistance to carbapenem and sulbactam [20,21]. Two
predominant genotypes related to European clone II were
found among isolates of A. baumannii contained bla (OXA-
23), and bla (OXA-24/40) [20].
Rising levels of carbapenem-resistant Acinetobacter spp. are
noticed in many countries. Warning of infections due to
carbapenem-resistant Acinetobacter spp. is required especially
when patients are relocated between hospitals. This will help
efforts to control the spread of carbapenem resistance [21]. The
synergistic effect of sulbactam/tazobactam in combination with
either meropenem or colistin to combat MDR A. baumannii
isolates has been implemented [22]. Colistin and meropenem
combination was also used to control extensively drug-
resistant and pandrug-resistant A. baumannii isolates [23,24].
The use of colistin in addition to vancomycin as a medicinal
choice against MDR A. baumannii infections particularly in
pediatric wards has been recommended [25].
The main limitation of this study is that it no molecular
analysis was done to trace the mode of transmission and identify
any outbreak linkage. Also, the sample size may be considered
comparatively small. This may result in a lack of authority to
establish the present of XDR or any other phenomena related to
the epidemiology of Acinetobacter spp. in ICU and the hospital
at large.
The present study concluded that all Acinetobacter spp. were
MDR. Virtually half of these strains were A. baumannii. These
were found 100% sensitive to colistin and to some extent to
trimethoprim + sulfamethoxazole (74.5%). A. baumannii com-
plex and A. baumannii/haemolyticus accounted for a substantial
ratio (48.6%) with sensitivities to the tested antimicrobials
similar to those given by members of the A. baumannii. Res-
piratory specimens in ICU represented a source for the majority
of the Acinetobacter spp. as it indicated ICU-acquired pneu-
monias. This predominates among patients over 60 years of age
who spend prolong times at artiﬁcial ventilation made up the
majority of the cases.Conﬂict of interest statement
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